Innovating Works

EUROPEAN LUNG FOUNDATION

Desconocido
RESPIRE-EXCEL: Respiratory Precision Medicine PhD Training Network Excellence through Systems Biology Spatial and... EUROPEAN LUNG FOUNDATION participó en un HORIZON EUROPE: HORIZON-MSCA-2023-DN-01 Asthma and COPD are prevalent, chronic respiratory diseases, with high incidence and societal costs. Current treatment is based on a ‘one-si...
2024-07-01 - 2029-02-28 | Financiado
OPTIMA: Optimal treatment for patients with solid tumours in Europe through Artificial intelligence EUROPEAN LUNG FOUNDATION participó en un H2020: H2020-JTI-IMI2-2020-23-two-stage OPTIMA is a multi-stakeholder-led consortium with the vision that each and every patient should have access to the most up-to-date individua...
2021-10-18 - 2026-09-30 | Financiado
UNITE4TB: ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS EUROPEAN LUNG FOUNDATION participó en un H2020: H2020-JTI-IMI2-2020-20-two-stage Current anti-tuberculosis (TB) drug regimens face serious limitations at times of increasing antimicrobial drug resistance. Fortunately, for...
2021-06-29 - 2028-05-31 | Financiado
EUREST-RISE: European Regulatory Science on Tobacco Research and Innovation Staff Exchange EUROPEAN LUNG FOUNDATION participó en un H2020: H2020-MSCA-RISE-2020 Smoking and other forms of tobacco consumption are considered the single most important cause of preventable morbidity and premature mortali...
2020-11-20 - 2025-05-31 | Financiado
DRAGON: The RapiD and SecuRe AI enhAnced DiaGnosis Precision Medicine and Patient EmpOwerment Centered Deci... EUROPEAN LUNG FOUNDATION participó en un H2020: H2020-JTI-IMI2-2020-21-single-stage In this project, a multinational consortium of high-tech SMEs, academic research institutes, biotech and pharma partners, affiliated patient...
2020-10-22 - 2024-03-31 | Financiado
discovAIR: Discovering the cellular landscape of the airways and the lung EUROPEAN LUNG FOUNDATION participó en un H2020: H2020-SC1-BHC-2018-2020 Lung diseases are a leading cause of death, with increasing incidence and lack of curative interventions. The development of novel therapeut...
2019-12-09 - 2022-06-30 | Financiado
FAIR: FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG RESISTA... EUROPEAN LUNG FOUNDATION participó en un H2020: H2020-SC1-BHC-2018-2020 Bacterial pneumonia is a leading cause of morbidity and mortality worldwide. Antibiotics constitute the standard of care but are faced with...
2019-12-06 - 2025-06-30 | Financiado
3TR: Identification of the Molecular Mechanisms of non response to Treatments Relapses and Remission in... EUROPEAN LUNG FOUNDATION participó en un H2020: H2020-JTI-IMI2-2018-14-two-stage 3TR is a transdisciplinary consortium made of experts in all areas of medicine, basic sciences and bioinformatics from academic institutions...
2019-08-22 - 2026-08-31 | Financiado
BETTER-B: BETTER TREATMENTS FOR BREATHLESSNESS IN PALLIATIVE AND END OF LIFE CARE EUROPEAN LUNG FOUNDATION participó en un H2020: H2020-SC1-BHC-2018-2020 The BETTER-B consortium tests whether mirtazapine, currently used as an antidepressant, is an effective treatment to reduce chronic or refra...
2018-12-03 - 2023-12-31 | Financiado
FRESH AIR: Free Respiratory Evaluation and Smoke exposure reductionby primary Health cAre Integrated gRoups EUROPEAN LUNG FOUNDATION participó en un H2020: H2020-HCO-2014-2015 FRESH AIR is a 3 year project which addresses the urgent need to prevent, diagnose and treat lung diseases in LMICs and other low-resource s...
2015-09-11 - 2018-09-30 | Financiado
U-BIOPRED: Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes EUROPEAN LUNG FOUNDATION participó en un FP6: RationaleThe inability of pre-clinical studies to predict clinical efficacy is a major bottleneck in drug development. In severe asthma this...
2009-10-01 - 2015-09-30 | Financiado
AirPROM: Airway Disease PRedicting Outcomes through Patient Specific Computational Modelling EUROPEAN LUNG FOUNDATION participó en un FP7: The airways diseases asthma and chronic obstructive pulmonary disease affect over 400 million people world-wide and cause considerable morbi...
Financiado
U-BIOPRED: Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes EUROPEAN LUNG FOUNDATION participó en un FP7: Rationale The inability of pre-clinical studies to predict clinical efficacy is a major bottleneck in drug development. In severe asthma thi...
Financiado
EARIP: European Asthma Research and Innovation Partnership EUROPEAN LUNG FOUNDATION participó en un FP7: Europe has 30 million people with asthma, whose treatment costs about €20 bn annually. Productivity lost through poor asthma control in Euro...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.